Swine flu vaccine linked to child narcolepsy: EU watchdog

A swine flu vaccine used in 2009-10 is linked to a higher risk of the sleeping disorder narcolepsy in children and teens in Sweden and Finland, the European Centre for Disease Prevention and Control said Friday.

The EU agency studied the effects of the Pandemrix vaccine on children in eight European countries after Sweden and Finland reported higher incidences of among children who were inoculated with the vaccine during the in 2009 and 2010.

"The case-control study found an association between vaccination with Pandemrix and an increased risk of narcolepsy in children and adolescents (five to 19 years of age) in Sweden and Finland," the ECDC said.

"The overall number of new cases of narcolepsy being reported after September 2009 was much higher in Sweden and Finland ... compared with the other countries participating in the study," it said.

In the six other countries—Britain, Denmark, France, Italy, The Netherlands and Norway—no link was found based on a strict statistical analysis, which tried to address .

However, other confirmatory analyses did identify an increased risk, the report said.

The report included several recommendations for further study to try to distinguish between true vaccine effects and media attention.

An ECDC spokesman said that while the study did not quantify the increased risk compared with non-vaccination, national studies showed the risk of developing narcolepsy after taking Pandemrix, which is produced by British drug company , was around one in 20,000 for children and adolescents.

Narcolepsy is a chronic that causes excessive drowsiness, often causing people to fall asleep uncontrollably, and in more severe cases to suffer hallucinations or paralysing physical collapses called cataplexy.

In Finland, 79 children aged four to 19 developed narcolepsy after receiving the Pandemrix vaccine in 2009 and 2010, while in Sweden the number was close to 200, according to figures in the two countries.

Both countries recommended their populations, of around five and 10 million respectively, to take part in mass vaccinations during the swine flu scare. Pandemrix was the only vaccine used in both countries.

Meanwhile, a recent study in the medical journal The Lancet said that between five and 17 people in Finland aged 0-17 are estimated to have died as a direct result of the 2009-10 swine flu pandemic, while the same number for Sweden was nine to 31.

In the past year, the Finnish and Swedish governments have both agreed to provide financial compensation for the affected children after their own national research showed a link between the inoculation and narcolepsy.

add to favorites email to friend print save as pdf

Related Stories

Swine flu vaccine likely causes child narcolepsy: study

Feb 01, 2011

Children injected with the Pandemrix swine flu vaccine were nine times more likely to contract narcolepsy than those who were not vaccinated, a preliminary study by Finland's National Institute for Health and Welfare, THL, ...

Sweden opens inquiry into suspect flu vaccine

Aug 18, 2010

Sweden's Medical Products Agency opened an inquiry Wednesday into vaccinations for swine flu made by British pharmaceutical company GlaxoSmithKline, suspected of provoking narcolepsy.

Recommended for you

Determine patient preferences by means of conjoint analysis

11 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments